Lutetium-177 Labelled PSMA Targeted Therapy in Advanced Prostate Cancer: Current Status and Future Perspectives

Cancers

Kambiz Rahbar¹  Robert Seifert¹  Wolfgang Roll¹  Katharina Kessel¹  Martin Boegemann²  Konstantin Egon Seitzer²  Katrin Schlack² 

[1] Department of Nuclear Medicine, University Hospital Muenster, 48149 Muenster, Germany;Department of Urology, University Hospital Muenster, 48149 Muenster, Germany;

关键词: prostate cancer;    castration-resistant;    prostate-specific membrane antigen;    radioligand therapy;    lutetium;   

DOI  :  10.3390/cancers13153715

来源: DOAJ

【 摘 要 】

Patients suffering from metastatic castration-resistant prostate cancer (mCRPC) have a poor prognosis. As a further treatment option ¹⁷⁷Lutetium (Lu) prostate-specific membrane antigen (PSMA) radioligand therapy gained a significant interest of many investigators. Several publications showed great response and prolonged survival with limited adverse events. However, to this point, it still remains unclear which patients benefit the most from ¹⁷⁷Lu-PSMA therapy, and how to improve the treatment regimen to achieve best outcome while minimizing potential adverse events. The efficacy for mCRPC patients is a given fact, and with the newly published results of the VISION trial its approval is only a matter of time. Recently, investigators started to focus on treating prostate cancer patients in earlier disease stages and in combination with other compounds. This review gives a brief overview of the current state and the future perspectives of ¹⁷⁷Lu labelled PSMA radioligand therapy.

【 授权许可】

Unknown